Navigation Links
Sigma-Tau Receives Innovation Award From The National Organization for Rare Disorders for Its Advancements in Rare Diseases
Date:5/15/2013

GAITHERSBURG, Md., May 15, 2013 /PRNewswire/ -- Sigma-Tau Pharmaceuticals, Inc. announced today that the Company was recognized last evening as a rare disease pioneer at the 30th anniversary celebration of The National Organization for Rare Disorders (NORD).  During the event, Sigma-Tau received an innovation award for the development of CYSTARAN™ (cysteamine ophthalmic solution) 0.44% --  the first and only approved therapy for the treatment of corneal cystine crystal accumulation in patients with cystinosis.

"NORD applauds Sigma-Tau Pharmaceuticals, NIH researchers, and patient organizations for collaborating to develop CYSTARAN for the treatment of this debilitating eye complication of cystinosis," said Peter L. Saltonstall , President and Chief Executive Officer of NORD. "As one of the first companies to receive an orphan-drug designation nearly 30 years ago, Sigma-Tau is once again demonstrating its strong and enduring commitment to serving rare disease communities with innovative products and effective patient programs."

Sigma-Tau developed CYSTARAN in partnership with the National Institutes of Health (NIH) and in cooperation with the Cystinosis Foundation, the Cystinosis Research Foundation, and the Cystinosis Research Network. The U.S. Food and Drug Administration (FDA) approved CYSTARAN for the treatment of this painful and debilitating eye condition in October 2012.

"We applaud NORD and all award recipients for their dedication to bringing innovative therapies and new hope to patients with rare diseases," said Dave Lemus , Chief Executive Officer of Sigma-Tau. "We are privileged to receive this award and remain committed to serving the rare disease community by developing and delivering innovative therapies."

Patient assistance programs for CYSTARAN are available, including co-pay assistance for eligible patients and access to CYSTARAN therapy for uninsured or under-insured patients.  Patients, caregivers and physicians in the United States and Puerto Rico can access the CYSTARAN Hotline at 1-800-440-0473, or by visiting the Accredo website, www.Accredo.com.

For full prescribing information for CYSTARAN, see www.cystaran.com.

Safety: The most frequently reported ocular adverse reactions occurring in >10% of patients were sensitivity to light, redness, eye pain/irritation, headache, and visual field defects.

About Cystinosis
Cystinosis, which affects approximately 2,000 individuals worldwide, is a rare metabolic disease in which the amino acid cystine enters cells, but has no transporter out of the cells. The defect in transportation leads to formation of crystals within the cells, causing early cell death. Cystinosis slowly destroys numerous vital organs including the kidneys, liver, eyes, muscles and the brain.  Corneal cystine accumulation can lead to ocular complications such as squinting, foreign body sensations, changes in visual acuity, corneal haziness and photophobia (i.e., sensitivity to light). Other complications of cystinosis include muscle weakness, diabetes, hypothyroidism, difficulty swallowing and rickets.  

About Sigma-Tau Pharmaceuticals
Sigma-Tau Pharmaceuticals, Inc. is a U.S.-based, wholly owned subsidiary of the Sigma-Tau Group, and is dedicated to the global development and commercialization of medicines for patients with rare diseases. Sigma-Tau Pharmaceuticals, Inc. is based in Gaithersburg, Maryland. Since 1989, the company's products have been focused on kidney disease, certain genetic disorders and cancers. With more than 7,000 identified rare diseases that affect approximately 30 million patients in the U.S. alone, Sigma-Tau places its considerable scientific resources behind the development and commercialization of compounds that benefit the few. The company has a substantial development program focused on transplant, cancer, inherited genetic disorders, malaria, and other areas of unmet medical need. For more information about the company, visit www.sigmatau.com.


'/>"/>
SOURCE Sigma-Tau Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Sigma-taus Antimalarial Awarded "Project of the Year" 2011 by Medicines for Malaria Venture
2. Stryker Receives Top Supplier Awards From Novation
3. CitiusTechs BI-Clinical Platform for Healthcare BI & Analytics Receives NCQA HEDIS Certification
4. Source One Management Services Receives SDCE 100 Award for 2013 Source One Wins Supply Chain Excellence for Eighth Consecutive Year
5. Actinium Pharmaceuticals, Inc. Receives Notice of Patent Allowance for a Key Application
6. China Jo-Jo Drugstores, Inc. Receives Delisting Notice from NASDAQ
7. Rosetta Genomics Receives Full Settlement Payment from Sanra Laboratories
8. Hill-Rom Receives FDA 510(k) Clearance to Market MetaNeb 4.0 Airway Clearance System
9. Fully Automated Diagnostic Device Receives CE Certification; IDx LLC Planning For Rollout Across Europe
10. AbbVies Investigational HCV Regimen Receives Breakthrough Therapy Designation from the U.S. Food and Drug Administration
11. STD Med, Inc. Receives Second Brazil GP Approval And Adds Med-Tech Regulatory Consulting Service
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2017)... , April 18, 2017 Viverae ® , ... announce the integration of IBM ® Watson Campaign ... deliver targeted communications for a personalized experience. Through digital ... on their health in real time. The enhanced experience ... most to members, wherever they are in their journey ...
(Date:4/18/2017)... , April 18, 2017  Astute Medical, Inc., ... case series to be presented at the 2017 National ... begins today and continues through April 22. Physicians will ... , used to assess risk for acute kidney injury ... heart failure (ADHF). Elevated levels of ...
(Date:4/18/2017)... Calif. , April 18, 2017  Socionext ... of collaboration started in 2016, in which Socionext ... Brain SOINN". The companies achieved initial results in ... solution by Artificial Brain SOINN. The results will ... Big Sight, April 19-21, at booths 4505 & ...
Breaking Medicine Technology:
(Date:4/24/2017)... MA (PRWEB) , ... April 24, 2017 , ... ... cardiovascular health of individuals with HIV because it is not known to have ... may have favorable effects to both lower cholesterol levels and dampen inflammation in ...
(Date:4/24/2017)... ... April 24, 2017 , ... Donna Parker, L. Ac. reads all sorts of ... of them to be very practical. She wanted to write a guide/workbook that would ... their health. It prompted her in writing “ A Clear Path to a Vibrant ...
(Date:4/24/2017)... ... April 24, 2017 , ... “The Saint with Trin, ... Trin, and Omega Station” is the creation of published author, Chris Jackson. Chris ... where he works in the Dallas Independent School District teaching English. He is heavily ...
(Date:4/24/2017)... ... 2017 , ... Anaconda BioMed, a pre-clinical stage medical device ... of Acute Ischemic Stroke (AIS), today announced it has appointed Creganna Medical to ... regulatory and clinical phases. , "This is another important step for Anaconda Biomed ...
(Date:4/22/2017)... North Carolina (PRWEB) , ... April 22, 2017 , ... ... in the United States estimated to be $394.9 billion. The consequences of rapid ... (and inevitably demolishes) the limits of technology, it is every business and individual’s job ...
Breaking Medicine News(10 mins):